bluuebunny/crossref_metadata_2025_split huggingface dataset:
Murine mammary tumor cells with a claudin-low genotype
Authors: Campbell Craig I , Thompson Devan E , Siwicky Megan D , Moorehead Roger A 
Published: August 2011

Abstract

Background
Molecular classification of human breast cancers has identified at least 5 distinct tumor subtypes; luminal A, luminal B, Her2-enriched, basal-like and claudin-low. The claudin-low subtype was identified in 2007 and is characterized by low expression of luminal differentiation markers and claudins 3, 4 and 7 and high levels of mesenchymal markers. Claudin-low tumors have a reported prevalence of 7-14% and these tumors have a poor prognosis.

Results
In this study we report the characterization of several cell lines established from mammary tumors that develop in MTB-IGFIR transgenic mice. Two lines, RM11A and RJ348 present with histological features and gene expression patterns that resemble claudin-low breast tumors. Specifically, RM11A and RJ348 cells express high levels of the mesenchymal genes Zeb1, Zeb2, Twist1 and Twist2 and very low levels of E-cadherin and claudins 3, 4 and 7. The RM11A and RJ348 cells are also highly tumorigenic when re-introduced into the mammary fat pad of mice.

Conclusions
Mammary tumor cells established from MTB-IGFIR transgenic mice can be used as in vitro and in vivo model systems to further our understanding of the poorly characterized, claudin-low, breast cancer subtype.
Polycation stabilization of graphene suspensions
Authors: ul Hasan Kamran , Sandberg Mats O , Nur Omer , Willander Magnus 
Published: August 2011

Abstract
Graphene is a leading contender for the next-generation electronic devices. We report a method to produce graphene membranes in the solution phase using polymeric imidazolium salts as a transferring medium. Graphene membranes were reduced from graphene oxides by hydrazine in the presence of the polyelectrolyte which is found to be a stable and homogeneous dispersion for the resulting graphene in the aqueous solution. A simple device with gold contacts on both sides was fabricated in order to observe the electronic properties.
Decline of influenza-specific CD8+ T cell repertoire in healthy geriatric donors
Authors: Lee Jessica B , Oelke Mathias , Ramachandra Lakshmi , Canaday David H , Schneck Jonathan P 
Published: August 2011

AbstractBackgroundWhile influenza vaccination results in protective antibodies against primary infections, clearance of infection is primarily mediated through CD8+T cells. Studying the CD8+T cell response to influenza epitopes is crucial in understanding the disease associated morbidity and mortality especially in at risk populations such as the elderly. We compared the CD8+T cell response to immunodominant and subdominant influenza epitopes in HLA-A2+control, adult donors, aged 21-42, and in geriatric donors, aged 65 and older.ResultsWe used a novel artificial Antigen Presenting Cell (aAPC) based stimulation assay to reveal responses that could not be detected by enzyme-linked immunosorbent spot (ELISpot). 14 younger control donors and 12 geriatric donors were enrolled in this study. The mean number of influenza-specific subdominant epitopes per control donor detected by ELISpot was only 1.4 while the mean detected by aAPC assay was 3.3 (p = 0.0096). Using the aAPC assay, 92% of the control donors responded to at least one subdominant epitopes, while 71% of control donors responded to more than one subdominant influenza-specific response. 66% of geriatric donors lacked a subdominant influenza-specific response and 33% of geriatric donors responded to only 1 subdominant epitope. The difference in subdominant response between age groups is statistically significant (p = 0.0003).ConclusionGeriatric donors lacked the broad, multi-specific response to subdominant epitopes seen in the control donors. Thus, we conclude that aging leads to a decrease in the subdominant influenza-specific CTL responses which may contribute to the increased morbidity and mortality in older individuals.
An evaluation of the preoperative hemoglobin level as a prognostic factor for oral squamous cell carcinoma
Authors: Cordella Claudia , Luebbers Heinz-Theo , Rivelli Valentina , Grätz Klaus W , Kruse Astrid L 
Published: August 2011

Abstract

Background
Hypoxia seems to be an influencing factor for oral squamous cell carcinomas (SCC), and several immunohistochemical markers have been discussed in this regard. The aim of the present study was to evaluate preoperative hemoglobin levels as a prognostic factor for oral SCC.

Materials and methods
The files of 287 patients who had been treated for oral SCC between 1999 and 2008 were studied retrospectively. Hemoglobin levels between 1 and 5 days prior to surgical treatment were compared to Tumor (T)- and Nodal (N)- status, local recurrence, and lymph node metastases rate. The minimum follow-up period was 12 months.

Results
From a total of 287 patients with oral SCC, 205 (71.4%) were in the normal hemoglobin (Hb) group (female Hb≥12.0 g/dl; male Hb≥13.0 g/dl), 53 (18.5%) in the mild anemia (female Hb = 11.0-11.9 g/dl; male Hb = 11.0-12.9 g/dl), and 29 (10.1%) in the severe anemia group (female & male Hb<11.0 g/dl). Anemia was significant for the development of lymph node metastasis (p = 0.005) as well as for local recurrence (p = 0.001). No significant correlation was found to the initial T status (p = 0.183).

Conclusion
Our data suggests that an Hb of below 11 g/dl contributes to and is an indicator for a poor prognosis. Consequently, pre-treatment Hb corrections may significantly improve outcome, but further investigations, including blood transfusion/application of erythropoietin due to tumor anemia, independent of intraoperative blood-loss are necessary to ascertain their role in an improved survival.
Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study
Authors: Innala Lena , Möller Bozena , Ljung Lotta , Magnusson Staffan , Smedby Torgny , Södergren Anna , Öhman Marie-Louise , Rantapää-Dahlqvist Solbritt , Wållberg-Jonsson Solveig 
Published: August 2011

Abstract
Introduction
Co-morbidity and mortality due to cardiovascular disease (CVD) are increased in patients with rheumatoid arthritis (RA). Most published studies in this field are retrospective or cross sectional. We investigated the presence of traditional and disease related risk factors for CVD at the onset of RA and during the first five years following diagnosis. We also evaluated their potential for predicting a new cardiovascular event (CVE) during the five-year follow-up period and the modulatory effect of pharmacological treatment.

Methods
All patients from the four northern-most counties of Sweden with early RA are, since December 1995, consecutively recruited at diagnosis (T0) into a large survey on the progress of the disease. Information regarding cardiovascular co-morbidity and related predictors was collected from clinical records and supplemented with questionnaires. By April 2008, 700 patients had been included of whom 442 patients had reached the five-year follow-up (T5).

Results
Among the 442 patients who reached T5 during the follow-up period, treatment for hypertension increased from 24.5 to 37.4% (P < 0.001)), diagnosis of diabetes mellitus (DM) from 7.1 to 9.5% (P < 0.01) whilst smoking decreased from 29.8 to 22.4% (P < 0.001) and the BMI from 26.3 to 25.8 (P < 0.05), respectively. By T5, 48 patients had suffered a new CVE of which 12 were fatal. A total of 23 patients died during the follow-up period. Age at disease onset, male sex, a previous CVE, DM, treatment for hypertension, triglyceride level, cumulative disease activity (area under the curve (AUC) disease activity score (DAS28)), extra-articular disease, corticosteroid use, shorter duration of treatment with disease modifying anti-rheumatic drugs (DMARDs) and use of COX-2 inhibitors increased the hazard rate for a new CVE. A raised erythrocyte sedimentation rate (ESR) at inclusion and AUC DAS28 at six months increased the hazard rate of CVE independently whilst DMARD treatment was protective in multiple Cox extended models adjusted for sex and CV risk factors. The risk of a CVE due to inflammation was potentiated by traditional CV risk factors.

Conclusions
The occurrence of new CV events in very early RA was explained by traditional CV risk factors and was potentiated by high disease activity. Treatment with DMARDs decreased the risk. The results may have implications for cardio-protective strategies in RA.
The non-protein coding breast cancer susceptibility locus Mcs5a acts in a non-mammary cell-autonomous fashion through the immune system and modulates T-cell homeostasis and functions
Authors: Smits Bart MG , Sharma Deepak , Samuelson David J , Woditschka Stephan , Mau Bob , Haag Jill D , Gould Michael N 
Published: August 2011

Abstract
Introduction
Mechanisms underlying low-penetrance, common, non-protein coding variants in breast cancer risk loci are largely undefined. We showed previously that the non-protein coding mammary carcinoma susceptibility locus Mcs5a/MCS5A modulates breast cancer risk in rats and women. The Mcs5a allele from the Wistar-Kyoto (WKy) rat strain consists of two genetically interacting elements that have to be present on the same chromosome to confer mammary carcinoma resistance. We also found that the two interacting elements of the resistant allele are required for the downregulation of transcript levels of the Fbxo10 gene specifically in T-cells. Here we describe mechanisms through which Mcs5a may reduce mammary carcinoma susceptibility.

Methods
We performed mammary carcinoma multiplicity studies with three mammary carcinoma-inducing treatments, namely 7,12-dimethylbenz(a)anthracene (DMBA) and N-nitroso-N-methylurea (NMU) carcinogenesis, and mammary ductal infusion of retrovirus expressing the activated HER2/neu oncogene. We used mammary gland and bone marrow transplantation assays to assess the target tissue of Mcs5a activity. We used immunophenotyping assays on well-defined congenic rat lines carrying susceptible and resistant Mcs5a alleles to identify changes in T-cell homeostasis and function associated with resistance.

Results
We show that Mcs5a acts beyond the initial step of mammary epithelial cell transformation, during early cancer progression. We show that Mcs5a controls susceptibility in a non-mammary cell-autonomous manner through the immune system. The resistant Mcs5a allele was found to be associated with an overabundance of gd T-cell receptor (TCR)+ T-cells as well as a CD62L (L-selectin)-high population of all T-cell classes. In contrast to in mammary carcinoma, gdTCR+ T-cells are the predominant T-cell type in the mammary gland and were found to be overabundant in the mammary epithelium of Mcs5a resistant congenic rats. Most of them simultaneously expressed the CD4, CD8, and CD161α markers. In cultured T-cells of Mcs5a resistant congenic rats we found increased mitogen-induced proliferation and production of Th1 cytokines IFNg, IL-2, and Tumor Necrosis Factor (TNF), but not Th2 cytokines IL-4 and IL-6, or Th17 cytokine IL-17 when compared with susceptible control rats.

Conclusions
These data support a hypothesis that Mcs5a displays a non-mammary cell-autonomous mechanism of action to modulate breast cancer risk through the immune system. The resistant Mcs5a allele is associated with alterations in T-cell homeostasis and functions, and overabundance of γδTCR+ T-cells in carcinogen-exposed mammary epithelium.
Statin pre-treatment is associated with lower platelet activity and favorable outcome in patients with acute non-cardio-embolic ischemic stroke
Authors: Tsai Nai-Wen , Lin Tsu-Kung , Chang Wen-Neng , Jan Chung-Ren , Huang Chi-Ren , Chen Shang-Der , Cheng Kuei-Yueh , Chiang Yi-Fang , Wang Hung-Chen , Yang Tzu-Ming , Lin Yu-Jun , Lin Wei-Che , Chang Hsueh-Wen , Lee Lian-Hui , Lu Cheng-Hsien 
Published: August 2011

Abstract
Introduction
Statins reportedly have anti-inflammatory and anti-thrombotic effects aside from cholesterol-lowering. This study aimed to evaluate the effect of pre-existing statin use on platelet activation markers and clinical outcome in acute ischemic stroke patients.

Methods
This prospective study evaluated 172 patients with acute ischemic stroke divided in two groups: patients with pre-existing statin (n = 43) and without pre-existing statin (66 cases with statins initiated post-stroke and 63 without statin treatment). Platelet activation markers (CD62P and CD63) were measured by flow cytometry at different time points after stroke and analyzed with clinical outcome.

Results
The CD62P and CD63 expressions on platelets were significantly lower in the patients with pre-existing statin use compared to the patients without pre-existing statin use on Day 1 post-stroke (p < 0.05). The CD62P expression was significantly lower in the patients with pre-existing statin use on 90 days after the acute stroke (p < 0.05). Patients with pre-existing statin use had lower incidences of early neurologic deterioration (END) than those without treatment (p < 0.05). Among several baseline clinical variables, admission NIHSS score, history of coronary artery disease, and pre-existing statin use were independent predictions of good clinical outcome at three months.

Conclusions
Pre-existing statin use is associated with decreased platelet activity as well as improved clinical outcome and reduced END in patients with acute ischemic stroke.
Succinylcholine versus rocuronium for rapid sequence intubation in intensive care: a prospective, randomized controlled trial
Authors: Marsch Stephan C , Steiner Luzius , Bucher Evelyne , Pargger Hans , Schumann Martin , Aebi Timothy , Hunziker Patrick R , Siegemund Martin 
Published: August 2011

Abstract
Introduction
Succinylcholine and rocuronium are widely used to facilitate rapid sequence induction (RSI) intubation in intensive care. Concerns relate to the side effects of succinylcholine and to slower onset and inferior intubation conditions associated with rocuronium. So far, succinylcholine and rocuronium have not been compared in an adequately powered randomized trial in intensive care. Accordingly, the aim of the present study was to compare the incidence of hypoxemia after rocuronium or succinylcholine in critically ill patients requiring an emergent RSI.

Methods
This was a prospective randomized controlled single-blind trial conducted from 2006 to 2010 at the University Hospital of Basel. Participants were 401 critically ill patients requiring emergent RSI. Patients were randomized to receive 1 mg/kg succinylcholine or 0.6 mg/kg rocuronium for neuromuscular blockade. The primary outcome was the incidence of oxygen desaturations defined as a decrease in oxygen saturation ≥ 5%, assessed by continuous pulse oxymetry, at any time between the start of the induction sequence and two minutes after the completion of the intubation. A severe oxygen desaturation was defined as a decrease in oxygen saturation ≥ 5% leading to a saturation value of ≤ 80%.

Results
There was no difference between succinylcholine and rocuronium regarding oxygen desaturations (succinylcholine 73/196; rocuronium 66/195; P = 0.67); severe oxygen desaturations (succinylcholine 20/196; rocuronium 20/195; P = 1.0); and extent of oxygen desaturations (succinylcholine -14 ± 12%; rocuronium -16 ± 13%; P = 0.77). The duration of the intubation sequence was shorter after succinycholine than after rocuronium (81 ± 38 sec versus 95 ± 48 sec; P = 0.002). Intubation conditions (succinylcholine 8.3 ± 0.8; rocuronium 8.2 ± 0.9; P = 0.7) and failed first intubation attempts (succinylcholine 32/200; rocuronium 36/201; P = 1.0) did not differ between the groups.

Conclusions
In critically ill patients undergoing emergent RSI, incidence and severity of oxygen desaturations, the quality of intubation conditions, and incidence of failed intubation attempts did not differ between succinylcholine and rocuronium.

Trial Registration
ClinicalTrials.gov, number NCT00355368.
Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage
Authors: Zhu Min , Yi Ming , Kim Chang Hee , Deng Chuxia , Li Yi , Medina Daniel , Stephens Robert M , Green Jeffrey E 
Published: August 2011

Abstract
Background
MicroRNAs (miRNAs) are small, non-coding, endogenous RNAs involved in regulating gene expression and protein translation. miRNA expression profiling of human breast cancers has identified miRNAs related to the clinical diversity of the disease and potentially provides novel diagnostic and prognostic tools for breast cancer therapy. In order to further understand the associations between oncogenic drivers and miRNA expression in sub-types of breast cancer, we performed miRNA expression profiling on mammary tumors from eight well-characterized genetically engineered mouse (GEM) models of human breast cancer, including MMTV-H-Ras, -Her2/neu, -c-Myc, -PymT, -Wnt1 and C3(1)/SV40 T/t-antigen transgenic mice, BRCA1
fl/fl
;p53+/-;MMTV-cre knock-out mice and the p53
fl/fl
;MMTV-cre transplant model.

Results
miRNA expression patterns classified mouse mammary tumors according to luminal or basal tumor subtypes. Many miRNAs found in luminal tumors are expressed during normal mammary development. miR-135b, miR-505 and miR-155 are expressed in both basal human and mouse mammary tumors and many basal-associated miRNAs have not been previously characterized. miRNAs associated with the initiating oncogenic event driving tumorigenesis were also identified. miR-10b, -148a, -150, -199a and -486 were only expressed in normal mammary epithelium and not tumors, suggesting that they may have tumor suppressor activities. Integrated miRNA and mRNA gene expression analyses greatly improved the identification of miRNA targets from potential targets identified in silico.

Conclusions
This is the first large-scale miRNA gene expression study across a variety of relevant GEM models of human breast cancer demonstrating that miRNA expression is highly associated with mammary tumor lineage, differentiation and oncogenic pathways.
Use of Models to Identify Cost-effective Interventions: Pertussis Vaccination for Pediatric Health Care Workers
Authors: Greer Amy L. , Fisman David N. 
Published: August 2011

OBJECTIVE:
Acellular pertussis vaccine is safe and effective in adults. An explicit recommendation for pertussis booster vaccination in pediatric health care workers is based on the importance of health care workers as a potential source of infection for patients. However, limited information is available on the economic attractiveness of this intervention. We sought to evaluate the health-economic attractiveness of a diphtheria-tetanus-acellular pertussis booster vaccination program for health care workers in a pediatric intensive care setting.

METHODS:
We developed a Markov model to calculate the cost-effectiveness of vaccinating NICU health care workers in different proportions ranging from the current strategy of no pertussis booster vaccination program to a vaccination program that achieves between 25% and 95% vaccine coverage.

RESULTS:
Implementation of a vaccination program that achieves 25% coverage was projected to be cost-saving compared with no vaccine program. At all coverage levels the intervention reduced costs, increased life expectancy, and was cost-effective. Projections were most sensitive to the risk of a pertussis introduction via an infected health care worker. Once the monthly risk of an introduction exceeded ∼0.3%, implementation of an immunization program with at least 25% coverage provided both greater health and greater economic benefits than having no vaccine program.

CONCLUSIONS:
The implementation of a hospital-based and funded diphtheria-tetanus-acellular pertussis vaccine program administered through an occupational health program is cost-effective or cost-saving in the context of pediatric health care facilities in which many of the patients are at risk of serious morbidity and mortality should they acquire pertussis while hospitalized.
CCVD Synthesis of Carbon‐Encapsulated Cobalt Nanoparticles for Biomedical Applications
Authors: Lukanov Petar , Anuganti Vijay K. , Krupskaya Yulia , Galibert Anne‐Marie , Soula Brigitte , Tilmaciu Carmen , Velders Aldrik H. , Klingeler Ruediger , Büchner Bernd , Flahaut Emmanuel 
Published: August 2011

AbstractCarbon‐encapsulated ferromagnetic Cobalt nanoparticles (Co@C) have been synthesized by catalytic chemical vapour deposition (CCVD). The nanoparticles, mainly ranging between 10 and 15 nm, are tightly encapsulated by 2–3 concentric graphitic carbon shells and protected from oxidation. Because of their magnetic properties (saturation magnetization of 106 emu/g and a coercivity HC of 250 Oe), Co@C nanoparticles have been investigated for hyperthermia application. Although the observed values of the specific absorption rate (28.7 W/gCo@C at 30 kA/m and 215.4 W/gCo@C at 70 kA/m) are slightly lower than required in actual hyperthermia therapies, the observed strong heating effect provides a very promising starting point for future clinical application. It is also demonstrated that these nanoparticles can at the same time be used for magnetic resonance imaging (MRI) with an efficiency comparable to commercially available T2 contrast agents.
ph‐Dependent Synthesis of Pepsin‐Mediated Gold Nanoclusters with Blue Green and Red Fluorescent Emission
Authors: Kawasaki Hideya , Hamaguchi Kenji , Osaka Issey , Arakawa Ryuichi 
Published: August 2011

AbstractThis report demonstrates the first pH‐dependent synthesis of pepsin‐mediated gold nanoclusters (AuNCs) with blue‐, green‐, and red‐fluorescent emission from Au5 (Au8), Au13, and Au25, respectively. Pepsin is a gastric aspartic proteinase (molecular weight, 34 550 g/mol) that plays an integral role in the digestive process of vertebrates. It was found that the pH of the reaction solution was critical in determining the size of Au NCs (i.e., the number of gold atoms of AuNCs). Interestingly, enzyme function of pepsin contributes to the formation of these AuNCs. The photo‐stability of the Au25 (or Au13) NCs is much higher than that of Au5NCs (i.e., Au25 ∼ Au13 > > Au5). The pepsin‐mediated Au25NCs were also found to be useful as fluorescent sensors for the detection of Pb2+ ions by enhanced fluorescence and the detection of Hg2+ ions by fluorescence quenching. Although the detailed formation mechanisms of these AuNCs require further analysis, the synthetic route using proteinase demonstrated here is promising for preparing new types of fluorescent metal nanoclusters for application in catalysis, optics, biological labeling, and sensing.
Tissue‐specific mosaicism for tetrasomy 9p uncovered by array CGH
Authors: Shehab Marwa I. , Mazen Inas , Bint Susan 
Published: August 2011

AbstractWe report on a patient with a mild clinical phenotype, including genital anomalies, with mosaic tetrasomy 9p. Karyotype analysis of peripheral blood lymphocytes detected a supernumerary isochromosome 9p present in every cell, with the initial result being reported as tetrasomy 9p in non‐mosaic form. However, array Comparative Genomic Hybridization (aCGH) studies on DNA extracted from peripheral blood lymphocytes and saliva showed that the patient had tissue‐specific mosaicism, with a lower level of abnormal cells in the saliva. These results correlate with the patient's clinical features as non‐mosaic cases of tetrasomy 9p have a more severe, often lethal, clinical phenotype. If non‐mosaic tetrasomy 9p is identified in a peripheral blood culture then examination of a different tissue type should be undertaken. Array CGH may be used as an alternative to karyotype analysis to estimate the level of mosaicism, and may eliminate the need for invasive skin biopsy as samples such as buccal smear and saliva can be used. Array CGH is able to detect mosaicism, establish the euchromatic content of supernumerary marker chromosomes, and identify imbalances elsewhere in the genome allowing more accurate counselling and prognosis for patients. © 2011 Wiley‐Liss, Inc.